logo
Plus   Neg
Share
Email

Soco International H1 Profit, Revenue Down On Weak Prices; Production Up

Soco International Plc. (SIA.L), an oil and gas exploration and production company, reported Wednesday that its first-half operating profit fell to $20.7 million from $27.8 million last year. Gross profit declined to $32.4 million from prior year's $38.3 million.

Group revenue was $91.8 million, down from last year's $93.2 million.

Total Group working interest production, however, grew to 12,541 boepd from 7,748 boepd last year.

Oil Price Realised dropped to $69.04 per barrel from $74.08 per barrel last year. Oil & Gas Price Realised declined to $61.96 per boe from $66.06 per boe a year ago.

Looking ahead, the company noted that in Egypt, production guidance for the El Fayum concession continues to be a 2019 exit rate of 6,500 bopd. In Vietnam, production guidance for 2019 remains unchanged at an average of 6,500-7,500 boepd for the full year

Further, SOCO said it will be hosting a Capital Markets Day on October 29.

SOCO is proposing to change its registered name to Pharos Energy plc. The change of name, in order to take effect, requires SOCO shareholders to pass a special resolution at a general meeting of the Company.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
New York Attorney General Letitia James has fled a lawsuit against Vyera Pharmaceuticals and two of its former CEOs, including imprisoned 'Pharma Bro' Martin Shkreli, for illegally monopolizing a life-saving drug Daraprim. The lawsuit seeks a lifetime ban on Shkreli and his business partner Kevin Mulleady working in the pharmaceutical industry. Graco Inc. (GGG) shares were climbing more than 7 percent in morning trade. Monday after market close, the company had reported a surge in the fourth-quarter earnings to $84.8 million from $73.7 million in the prior year. Earnings per share surpassed analysts' estimates. Sales were up 1 percent to $412.3... Strategy of getting multiple indication approvals for the same drug seems to be paying off for AstraZeneca PLC (AZN), in terms of higher likelihood of approval and improved sales. Besides, the company is realizing value from non-core, mature brands to invest in new drugs, which also seems to be working in its favor.
Follow RTT
>